Table 1.

Study Characteristics

Trial characteristics	N (%) (N = 20)
Randomized	11 (55.0)
Non-randomized	9 (45.0)
Phase II study	12 (60.0)
Phase III study	8 (40.0)
US based enrollment	9 (45.0)
Non-US-based enrollment	11 (55.0)
Studies including high-risk patients	19 (95.0)
Primary end point(s)
Response based	3 (25.0)
PFS based	6 (30.0)
OS based	2 (10.0)
MRD status	11 (55.0)
Incidence of death based	1 (5.0)
Proportion able to complete 1 year therapy	1 (5.0)
FACT-MM TOI score	1 (5.0)

PFS= progression free survival; OS= overall survival; MRD= Minimal residual disease; FACT-MM TOI= Functional assessment of cancer therapy - multiple myeloma trial outcome index